Preclinical Success to Clinical Failure: Do We Have a Model Problem or an Endpoint Problem?

As the AACR (American Association for Cancer Research) Annual Meeting is fast approaching, many industry and academic scientists are busy preparing talks and posters for what they hope will be the next new wave in cancer therapy or the next “new and improved” preclinical model. However, while these may be long shots, it’s the scientific […]

Colo-205 as a Translational Imaging Model for Colorectal Cancer

As mentioned in our HT-29 Model Spotlight last October, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States for men and women combined. The death rate from CRC has been declining over the past several decades and there are now more than one million CRC survivors in the United […]

PC-3M-Luc-C6 – A Model for Prostate Carcinoma

Globally, prostate cancer is the second most common type of cancer in men.  Prostate cancer is found mainly in older men with approximately 99 percent occurring in men over the age of 50. In the United States, African American men are roughly 70 percent more likely to be diagnosed with […]

Measuring Extracellular pH Within Tumors Using CEST MRI

pH is one of the key microenvironmental factors in the development of tumors. Tumor cells are often viewed as high lactate and H+ producers.1 Extracellular acidosis represents a threat to cell survival by modifying the intracellular pH (pHi), wherein a 0.1 pHi variation can disrupt multiple biological functions.2 Measurements of tumor extracellular pH (pHe) may […]

Longitudinal Evaluation of Orthotopic Lung Tumors With Imaging

Lung cancer is the most common cause of cancer related deaths for men and second for women (after breast cancer). Worldwide, 1.8 million diagnoses and 1.6 million deaths occur annually.1 While incidences have been decreasing over recent decades and advances in diagnosis and treatments are being made in cancer as […]

786-O (pMMP-LucNeo) – A Model for Renal Cell Carcinoma

Kidney cancer generally occurs in older people, with an average age of diagnosis at 64 years old. Kidney cancer is among the ten most common types of cancer in the United States, with an overall lifetime risk of approximately 1.6 percent. The most common form of kidney cancer is renal […]

Leveraging the Clinical Power of MRI in Preclinical Liver Tumor Imaging

The liver is an ideal organ for magnetic resonance imaging (MRI) due to its size, plus the inherent contrast it enables compared to other tissues and lesions; this results from the high iron content which acts as a natural MRI contrast agent. For such reasons, liver tumor MRI is a major area of clinical and […]

Approaches for Preclinical Evaluation of Ovarian Cancer

Table 1: Ovarian Cancer Models Ovarian cancer is considered a relatively rare gynecologic malignancy but has one of the highest mortality rates due to the non-specific symptoms that occur in early stage disease. This results in most women being diagnosed with advanced stage disease. The incidence of ovarian cancer within […]

Evaluation of the Immune Response Following Treatment with Anti-CTLA-4 Antibody, Radiation Therapy, or the Combination in Murine Model of Breast Cancer

Breast cancers are considered poorly immunogenic tumors, however, several approaches utilizing immunotherapies are being undertaken in the clinic to evaluate their potential for improving outcomes. Radiation therapy (RT) is a highly utilized clinical treatment modality in breast cancer. Radiation is known to modify the tumor microenvironment, induce cytokines and chemokines, and has been shown to […]

Access the Power of Focal Beam Radiation Using Xstrahl’s SARRP

Radiation therapy is one of the most common treatments for cancer. Approximately 60 percent of cancer patients will receive radiation treatment at some point during their care. Its clinical prevalence makes understanding how novel cancer treatments may synergize with radiation therapy vital to drug development. Radiation therapy treatment uses high-energy […]

Comparison of Bioluminescence and MR Imaging to Evaluate Orthotopic Glioma Models

Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. These tumors are usually highly malignant because the cells reproduce quickly and they are supported by a large network of blood vessels. GBM is the […]

PET Quantification of Receptor Occupancy

The use of PET imaging to detect and quantify receptor occupancy (RO) has become a translational standard in CNS discovery and clinical trials. For example, 18F radiolabeling of targeted small molecules enables a PET tracer-based PD biomarker. The tracer can be used for dynamic, non-invasive quantification of percentage RO. For relevant targets, rodent models can […]

GL261: Syngeneic Murine Glioma Model

Glioblastomas are known to have a poor prognosis with median survival of nine months and only five to 10 percent of patients surviving up to two years. Conventional therapies include radiotherapies and surgical removal of the tumor in combination with chemotherapy. Unfortunately, these tumors can often be radioresistant and surgical […]

Precision Imaging of Antibody Biodistribution in vivo With Zirconium-89 PET

Zirconium-89 (89Zr) has revolutionized discovery and translation of Ab (and Ab fragment) therapeutics via PET biodistribution imaging.  With standard, straightforward labeling chemistry, 89Zr provides unprecedented specificity and sensitivity of PET Ab detection (to pM levels).  At MI Bioresearch we use 89Zr PET as a platform assay for in vivo quantification of: Ab targeting precision Off […]

Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial

With the ability to provide non-invasive, three dimensional, longitudinal, and quantitative data—PET, SPECT, and fluorescence imaging (FMT) enable translational imaging of: Biodistribution Targeting Kinetics Clearance Pathways In vivo biodistribution imaging applications are now critical assays for biologics characterization for discovery screening, lead candidate selection/optimization and safety. At MI Bioresearch (MI) we combine highly sensitive PET, SPECT, […]